

# OIE Reference Laboratory Reports Activities

## *Activities in 2020*

**This report has been submitted : 2021-01-18 08:12:44**

<b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b>	Brucellosis (Brucella abortus, B. melitensis, B. canis)
<b>Address of laboratory:</b>	P.O. Box 597 Dubai UNITED ARAB EMIRATES
<b>Tel.:</b>	+971-4 337.51.65
<b>Fax:</b>	+971-4 336.86.38
<b>E-mail address:</b>	cvrl@cvrl.ae
<b>Website:</b>	www.cvrl.ae
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Priv. Doz. Dr. Dr. habil.Ulrich Wernery
<b>Name (including Title and Position) of OIE Reference Expert:</b>	Priv. Doz. Dr. Dr. habil.Ulrich Wernery Scientific Director
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

**ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards**

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
CFT	Yes	92	0
RBT	Yes	1,692	0
SAT	Yes	3	0
ELISA	Yes	223	0
RSAT (B. canis)	Yes	117	10
IFAT (B. canis)	Yes	27	0
Direct diagnostic tests			
Culture	Yes	437	0
PCR (B. abortus and B. melitensis)	Yes	2	0

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.  
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

**ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases**

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

**ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries**

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
INDIA	January-December	1	0
MAURITIUS	January-December	3	0
OMAN	January-December	4	0
SEYCHELLES	January-December	2	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
ISRAEL	serological testing during B. canis outbreak	e-mail

**ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations**

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Investigation of DNA sequences of Brucella strains isolated from the UAE compared to the DNA sequences of Brucella isolated from Israel	2-3 years	To produce a novel vaccine using nanotechnology which is based on unique strains from this area	Kimron Veterinary Institute	ISRAEL
Brucella strains- Molecular Fingerprinting	2 years	Determining the genotypes of B. melitensis isolates from dromedary camel and other host species from the UAE	Institute for Veterinary Medical Research, Hungarian Academy of science	HUNGARY

**ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases**

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:
Brucellosis epizootiological data should be collected by Municipality and Ministry of Climate Change and Environment(MOCCAE)in cooperation with CVRL which has not happened so far.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:

Since many years CVRL disseminates Brucellosis results of many different animal species in the UAE to the Ministry of Climate Change and Environment (MOCCA) which are also laid down in CVRL annual report. Additionally many meetings with Municipality and MOCCA have taken place at CVRL with the purpose how to eradicate Brucellosis from this country as well as vaccination program.

**13. What method of dissemination of information is most often used by your laboratory?  
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 0

c) National conferences: 0

d) Other:  
(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries  
To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO/IEC 17025:2017	4. CVRL ISO cert_scope_appendix -2.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
African Horse Sickness	IAS, USA
Equine Piroplasmiasis	IAS, USA
Equine Infectious Anaemia	IAS, USA
Equine Viral Arteritis	IAS, USA
Glanders	IAS, USA
Dourine	IAS, USA
CEM	IAS, USA
Brucellosis	IAS, USA
West Nile	IAS, USA
Strangles	IAS, USA
EHV 1& 4	IAS, USA
Influenza A virus isolation	IAS, USA
Avian Paramyxovirus Type -1 (APMV-1) virus isolation	IAS, USA
Equine arteritis virus isolation from semen	IAS, USA
MERS	IAS, USA
ELISA technique for various diseases	IAS, USA
CFT technique for various diseases	IAS, USA
AGID technique for various diseases	IAS, USA

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Brucella strains isolated from the UAE compared to the DNA sequences of Brucella strains isolated from Israel	To produce a novel vaccine using nanotechnology which is based on the unique strains of this area	Kimron Veterinary Institute, Israel

**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at:  
<http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

**ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
E-mail correspondence with OIE technical committee	UAE	Amendment of the OIE chapter for Brucellosis

25. Additional comments regarding your report: